A Arcaro

Summary

Affiliation: University of Bern
Country: Switzerland

Publications

  1. ncbi request reprint Phosphatidylinositol 3-kinase isoforms as novel drug targets
    Karolina Błajecka
    University of Bern, Department of Clinical Research, Bern, Switzerland
    Curr Drug Targets 12:1056-81. 2011
  2. ncbi request reprint A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance
    Ana S Guerreiro
    Department of Oncology, University Children s Hospital, Zurich, Switzerland
    Mol Cancer Res 9:925-35. 2011
  3. pmc NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma
    Giulio Fiaschetti
    Department of Oncology, University Children s Hospital of Zurich, Zurich, Switzerland
    Acta Neuropathol Commun 2:39. 2014
  4. pmc Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma
    Katrin Höland
    Department of Clinical Research, University of Bern, Bern, Switzerland
    PLoS ONE 9:e94132. 2014
  5. pmc Emerging metabolic targets in the therapy of hematological malignancies
    Zaira Leni
    University of Bern, Department of Clinical Research, Division of Pediatric Hematology Oncology, Murtenstrasse 31, 3010 Bern, Switzerland
    Biomed Res Int 2013:946206. 2013
  6. pmc Targeting the insulin-like growth factor-1 receptor in human cancer
    Alexandre Arcaro
    Division of Pediatric Hematology Oncology, Department of Clinical Research, University of Bern Bern, Switzerland
    Front Pharmacol 4:30. 2013
  7. pmc Phosphoinositide 3-kinase C2β regulates RhoA and the actin cytoskeleton through an interaction with Dbl
    Karolina Błajecka
    Department of Clinical Research, University of Bern, Bern, Switzerland
    PLoS ONE 7:e44945. 2012
  8. pmc Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma
    Anna Wojtalla
    Division of Pediatric Hematology Oncology, Department of Clinical Research, University of Bern, Switzerland
    PLoS ONE 7:e47109. 2012
  9. pmc Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: therapeutic implications
    Alexandre Arcaro
    Department of Clinical Research, University of Bern, Switzerland
    Autophagy 9:607-8. 2013
  10. ncbi request reprint Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours
    Danielle Boller
    Division of Clinical Chemistry and Biochemistry, University Children s Hospital Zurich, Zurich, Switzerland
    Anticancer Res 32:3015-27. 2012

Collaborators

  • I Zlobec
  • N Gross
  • Laura Leitner
  • Michael A Grotzer
  • Tarek Shalaby
  • Karolina Błajecka
  • Katrin Höland
  • Zaira Leni
  • Danielle Boller
  • F Salm
  • K Holand
  • Ana S Guerreiro
  • Giulio Fiaschetti
  • Karl Frei
  • Paulina Cwiek
  • Fabiana Salm
  • Anna Wojtalla
  • Marin Marinov
  • Olivier Delattre
  • Sarah Fattet
  • G Fiaschetti
  • Christina Schroeder
  • Silvia Dolski
  • Beata Styp-Rekowska
  • Martin Baumgartner
  • Christian Hagel
  • Frank Westermann
  • Andre O Von Bueren
  • Deborah Castelletti
  • Olivier E Pardo
  • Valentin Djonov
  • Peter R Shepherd
  • Andras Treszl
  • A Lucia Buccarello
  • S C Schafer
  • C Wotzkow
  • F Westermann
  • P Cwiek
  • Geetha Parakkal
  • B Styp-Rekowska
  • V Djonov
  • F Largey
  • A Ghosal
  • N Bodmer
  • Ditte G Christiansen
  • Angela De Laurentiis
  • Guido Posern
  • Paul Depledge
  • Tomonobu Koizumi
  • Takahide Ohishi
  • Michael D Waterfield
  • Kathrin T Doepfner
  • Hiroyuki Kaizawa
  • Olivier Spertini
  • Kristin Uth
  • Anelia Schweri-Olac
  • Tiziana Cremona
  • Anthony Robson
  • Masahiko Hayakawa
  • Nahid Saghir
  • Anna Borgström
  • T Shalaby
  • Dorota W Kulesza
  • Shaun P Jackson
  • D Castelletti
  • Abdullah Atamer
  • Simone M Schoenwaelder
  • Alexandra N Elsing

Detail Information

Publications13

  1. ncbi request reprint Phosphatidylinositol 3-kinase isoforms as novel drug targets
    Karolina Błajecka
    University of Bern, Department of Clinical Research, Bern, Switzerland
    Curr Drug Targets 12:1056-81. 2011
    ..In addition, we will describe the drugs currently used in clinical trials, as well as promising emerging candidates...
  2. ncbi request reprint A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance
    Ana S Guerreiro
    Department of Oncology, University Children s Hospital, Zurich, Switzerland
    Mol Cancer Res 9:925-35. 2011
    ..Together, our data show that the p110γ phosphoinositide 3-kinase isoform is a novel target for combinatorial therapies in medulloblastoma...
  3. pmc NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma
    Giulio Fiaschetti
    Department of Oncology, University Children s Hospital of Zurich, Zurich, Switzerland
    Acta Neuropathol Commun 2:39. 2014
    ..Finally, the positive correlation of MYC and JAG2 also with aggressive anaplastic tumors and highly metastatic MB stages suggested that high JAG2 expression may be useful as additional marker to identify aggressive MBs...
  4. pmc Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma
    Katrin Höland
    Department of Clinical Research, University of Bern, Bern, Switzerland
    PLoS ONE 9:e94132. 2014
    ..Together, our data reveal that drugs targeting PI3K p110α can reduce growth in a subset of glioblastoma tumors characterized by the expression of EGFR/PI3K p110α/p-S6. ..
  5. pmc Emerging metabolic targets in the therapy of hematological malignancies
    Zaira Leni
    University of Bern, Department of Clinical Research, Division of Pediatric Hematology Oncology, Murtenstrasse 31, 3010 Bern, Switzerland
    Biomed Res Int 2013:946206. 2013
    ..The identification of the metabolic enzymes critical for hematological cancer cell proliferation and survival appears to be an interesting new approach for the targeted therapy of hematological malignancies. ..
  6. pmc Targeting the insulin-like growth factor-1 receptor in human cancer
    Alexandre Arcaro
    Division of Pediatric Hematology Oncology, Department of Clinical Research, University of Bern Bern, Switzerland
    Front Pharmacol 4:30. 2013
    ..In this mini review, I will discuss the role of the IGF signaling system in human cancer and the main strategies which have been so far evaluated to target the IGF-1R...
  7. pmc Phosphoinositide 3-kinase C2β regulates RhoA and the actin cytoskeleton through an interaction with Dbl
    Karolina Błajecka
    Department of Clinical Research, University of Bern, Bern, Switzerland
    PLoS ONE 7:e44945. 2012
    ..Taken together, these findings suggest that PI3KC2β modulates the cell morphology and survival through a specific interaction with Dbl and the activation of RhoA...
  8. pmc Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma
    Anna Wojtalla
    Division of Pediatric Hematology Oncology, Department of Clinical Research, University of Bern, Switzerland
    PLoS ONE 7:e47109. 2012
    ..Hopefully, this knowledge will contribute to the development of urgently required new targeted therapies for embryonal tumors...
  9. pmc Involvement of autophagy in the response of tumor cells to PtdIns3K inhibitors: therapeutic implications
    Alexandre Arcaro
    Department of Clinical Research, University of Bern, Switzerland
    Autophagy 9:607-8. 2013
    ..A better understanding of the contribution of autophagy to the action of PI3K inhibitors on tumors cells is important, since it may limit or enhance the action of these compounds, depending on the cellular context...
  10. ncbi request reprint Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours
    Danielle Boller
    Division of Clinical Chemistry and Biochemistry, University Children s Hospital Zurich, Zurich, Switzerland
    Anticancer Res 32:3015-27. 2012
    ..Eight human catalytic phosphoinositide 3-kinase (PI3K) isoforms exist which are subdivided into three classes. While class I isoforms have been well-studied in cancer, little is known about the functions of class II PI3Ks...
  11. ncbi request reprint Quassinoids: From traditional drugs to new cancer therapeutics
    G Fiaschetti
    Department of Oncology, University Children s Hospital, Zurich, Switzerland
    Curr Med Chem 18:316-28. 2011
    ..Here, we review available knowledge of functionality and possible applications of quassinoids and quassinoid derivatives, spanning traditional use to the potential impact on modern medicine as cancer therapeutics...
  12. ncbi request reprint RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance
    F Salm
    Department of Clinical Research, University of Bern, Bern, Switzerland
    Oncogene 32:3944-53. 2013
    ..These findings suggest a novel role for FGFR2 in chemoresistance and provide a rational to combine pharmacological inhibitors against FGFR2 with chemotherapeutic agents for the treatment of NB...
  13. ncbi request reprint The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors
    K Holand
    University of Bern, Department of Clinical Research, Bern, Switzerland
    Curr Cancer Drug Targets 11:894-918. 2011
    ....